HealthBeacon Interim CFO appointed Chief Financial Officer
Company bolsters management team as it pursues growth
HealthBeacon plc ("HealthBeacon" or "the Company"), a leader in devices and software to manage critical and chronic medications, today announces the appointment of Lar Malone as Chief Financial Officer. Lar has served as Interim CFO since joining the Company in December 2022.
A Chartered Management Accountant with significant finance and management experience at CFO level, Lar has held a number of senior roles within the pharmaceutical industry, including with Pfizer, Schering-Plough, Teva and Alexion.
Jim Joyce, Co-Founder and Chief Executive of HealthBeacon, commented: "I am very pleased that Lar has been appointed HealthBeacon's Chief Financial Officer. Since joining the Company as Interim CFO last year, Lar has made a significant contribution to HealthBeacon, bringing his excellent expertise to bear within our finance function, and actively supporting the Company's growth aspirations. Lar has extensive experience in the pharmaceutical industry and will be a valuable asset to HealthBeacon as we continue to expand our client base, grow technology deployments, and deliver on the significant growth opportunity ahead."
| Enquiries: |
Investor.Relations@HealthBeacon.com |
| HealthBeacon: Jim Joyce Lar Malone
|
|
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Paul Clifford |
+353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.